Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: A systematic review and meta-analysis

Medical Oncology

Volumn 32, Issue 1, 2015, Pages

  Liu, Xinyu ^a   Ma, Ding ^a   Jing, Xiaoqian ^a   Wang, Bingrui ^a   Yang, Weiping ^a   Qiu, Weihua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ANXA2; Disease free survival; Malignant tumor; Meta analysis; Overall survival

Indexed keywords

LIPOCORTIN 2; ANXA2 PROTEIN, HUMAN; TUMOR MARKER;

ADVERSE OUTCOME; AGE DISTRIBUTION; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; OVERALL SURVIVAL; SYSTEMATIC REVIEW; TUMOR INVASION; BIOSYNTHESIS; MORTALITY; NEOPLASM; PATHOLOGY; PROGNOSIS; UPREGULATION;

ANNEXIN A2; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; PROGNOSIS; UP-REGULATION;

EID: 84920197820     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0392-y     Document Type: Article

References (28)

1. Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–74.
2. Fritz S, Hackert T, Hinz U, Hartwig W, Büchler M, Werner J. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg. 2011;98(1):104–10.
3. Blank S, Wang Q, Fiel MI, Luan W, Kim KW, Kadri H, et al. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis b-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol. 2014;21(3):986–94.
4. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11(7):481–92.
5. 2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6(6):449–61.
6. Rescher U, Gerke V. Annexins—unique membrane binding proteins with diverse functions. J Cell Sci. 2004;117(13):2631–9.
7. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82(2):331–71.
8. Chuthapisith S, Bean BE, Cowley G, Eremin JM, Samphao S, Layfield R, et al. Annexins in human breast cancer: possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer. 2009;45(7):1274–81.
9. Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001;21(2B):1339–45.
10. Gao H, Yu B, Yan Y, Shen J, Zhao S, Zhu J, et al. Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis: laboratory investigation. J Neurosurg. 2013;118(4):846–53.
11. Ma R-L, Shen L-Y, Chen K-N. Coexpression of ANXA2, SOD2 and HOXA13 predicts poor prognosis of esophageal squamous cell carcinoma. Oncol Rep. 2014;31(5):2157–64.
12. Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M. Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer. 2009;101(2):287–94.
13. Seckinger A, Meiβner T, Moreaux J, Depeweg D, Hillengass J, Hose K, et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012;120(5):1087–94.
14. Wang C-Y, Chen C-L, Tseng Y-L, Fang Y-T, Lin Y-S, Su W-C, et al. Annexin A2 silencing induces G2 arrest of non-small cell lung cancer cells through p53-dependent and-independent mechanisms. J Biol Chem. 2012;287(39):32512–24.
15. Yang T, Peng H, Wang J, Yang J, Nice E, Xie K, et al. Prognostic and diagnostic significance of annexin A2 in colorectal cancer. Colorectal Dis. 2013;15(7):e373–81.
16. Yonglitthipagon P, Pairojkul C, Chamgramol Y, Mulvenna J, Sripa B. Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol. 2010;40(10):1203–12.
17. Zhang Q, Zhao Z, Ma Y, Wang H, Ma J, He X et al., editors. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations; 2014: Elsevier.
18. Duncan R, Carpenter B, Main L, Telfer C, Murray G. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer. 2007;98(2):426–33.
19. Ding T, Yang L, Wang Y, Yuan J, Chen T, Cai X. Down-regulation of annexin II in prostate cancer is associated with Gleason score, recurrence, metastasis and poor prognosis. Mol Med Rep. 2010;3(5):781–7.
20. Rodrigo JP, García-Pedrero JM, Llorente JL, Fresno MF, Allonca E, Suarez C, et al. Down-regulation of annexin A1 and A2 protein expression in intestinal-type sinonasal adenocarcinomas. Hum Pathol. 2010;42(1):88–94.
21. Rodrigo JP, Lequerica-Fernández P, Rosado P, Allonca E, García-Pedrero JM, de Vicente JC. Clinical significance of annexin A2 downregulation in oral squamous cell carcinoma. Head Neck. 2010;33(12):1708–14.
22. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16.
23. Higgins J, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
24. Alonso-Alconada L, Santacana M, Garcia-Sanz P, Muinelo-Romay L, Colas E, Mirantes C, et al. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. Int J Cancer. 2014. doi:10.1002/ijc.29213.
25. Raynal P, Pollard HB. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium-and phospholipid-binding proteins. Biochimi Biophysi Acta. 1994;1197(1):63–93.
26. Moss SE, Morgan RO. The annexins. Genome Biol. 2004;5(4):219.
27. Filipenko NR, MacLeod TJ, Yoon C-S, Waisman DM. Annexin A2 is a novel RNA-binding protein. J Biol Chem. 2004;279(10):8723–31.
28. Flood EC, Hajjar KA. The annexin A2 system and vascular homeostasis. Vasc Pharmacol. 2011;54(3):59–67.